Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive ...

Gov. Brian Kemp signed into law an overhaul of the state's litigation system aimed at bringing down insurance costs.

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

NASDAQ MYGN opened at $7.95 on Friday. Myriad Genetics, Inc. has a 52 week low of $7.35 and a 52 week high of $29.30. The firm has a market capitalization of $725.91 million, a price-to-earnings ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to Neutral. Analyst Price Forecast Suggests 107.09% Upside As of April 1 ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the ...